Anti-PD-L1 Lead-in Before MAPKi Combination Maximizes Anti-Tumor Efficacy and Immunity.
Ontology highlight
ABSTRACT: Anti-PD-L1 Lead-in Before MAPKi Combination Maximizes Anti-Tumor Efficacy and Immunity.
PROVIDER: PRJNA737158 | ENA |
REPOSITORIES: ENA
ACCESS DATA